p53 as a therapeutic target

O. D. Staples, R. J. C. Steele, S. Lain

    Research output: Contribution to journalReview article

    20 Citations (Scopus)

    Abstract

    Since the discovery of p53, a vast wealth of knowledge on its function and regulation has been accumulated. It is known that it is a key tumour suppressor and that its function is lost in many types of cancers, either by mutation or by excessive negative regulation. Recently, several discoveries have re-energised p53 as a therapeutic target as it has been shown that reintroduction of functional p53 into tumours has a therapeutic benefit. These encouraging results clearly justify the search for small molecules that diminish negative regulation Of p53 in tumour cells, where p53 is not mutated as well as compounds that reactivate mutant p53. Important findings have been made to deal with both situations. Additionally, some of the small molecules identified may also help reduce the side effects of commonly used cancer therapeutics. These studies are still in their infancy and require further therapeutic validation, but the future appears bright for finally harnessing p53's tumour suppressing ability.

    Original languageEnglish
    Pages (from-to)240-243
    Number of pages4
    JournalSurgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
    Volume6
    Issue number4
    Publication statusPublished - Aug 2008

    Keywords

    • p53
    • Therapy
    • Tenovin
    • Prima
    • Nutlin
    • Tumor suppressor P53
    • Wild type P53
    • Nuclear export
    • SV40 transformed cells
    • Cancer therapy
    • Breast cancer
    • Mutant P53
    • MDM2
    • Activation
    • Pathway

    Cite this

    @article{00a5951275084f26941c18db851161ed,
    title = "p53 as a therapeutic target",
    abstract = "Since the discovery of p53, a vast wealth of knowledge on its function and regulation has been accumulated. It is known that it is a key tumour suppressor and that its function is lost in many types of cancers, either by mutation or by excessive negative regulation. Recently, several discoveries have re-energised p53 as a therapeutic target as it has been shown that reintroduction of functional p53 into tumours has a therapeutic benefit. These encouraging results clearly justify the search for small molecules that diminish negative regulation Of p53 in tumour cells, where p53 is not mutated as well as compounds that reactivate mutant p53. Important findings have been made to deal with both situations. Additionally, some of the small molecules identified may also help reduce the side effects of commonly used cancer therapeutics. These studies are still in their infancy and require further therapeutic validation, but the future appears bright for finally harnessing p53's tumour suppressing ability.",
    keywords = "p53, Therapy, Tenovin, Prima, Nutlin, Tumor suppressor P53, Wild type P53, Nuclear export, SV40 transformed cells, Cancer therapy, Breast cancer, Mutant P53, MDM2, Activation, Pathway",
    author = "Staples, {O. D.} and Steele, {R. J. C.} and S. Lain",
    year = "2008",
    month = "8",
    language = "English",
    volume = "6",
    pages = "240--243",
    journal = "Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland",
    issn = "1479-666X",
    publisher = "Elsevier",
    number = "4",

    }

    p53 as a therapeutic target. / Staples, O. D.; Steele, R. J. C.; Lain, S.

    In: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, Vol. 6, No. 4, 08.2008, p. 240-243.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - p53 as a therapeutic target

    AU - Staples, O. D.

    AU - Steele, R. J. C.

    AU - Lain, S.

    PY - 2008/8

    Y1 - 2008/8

    N2 - Since the discovery of p53, a vast wealth of knowledge on its function and regulation has been accumulated. It is known that it is a key tumour suppressor and that its function is lost in many types of cancers, either by mutation or by excessive negative regulation. Recently, several discoveries have re-energised p53 as a therapeutic target as it has been shown that reintroduction of functional p53 into tumours has a therapeutic benefit. These encouraging results clearly justify the search for small molecules that diminish negative regulation Of p53 in tumour cells, where p53 is not mutated as well as compounds that reactivate mutant p53. Important findings have been made to deal with both situations. Additionally, some of the small molecules identified may also help reduce the side effects of commonly used cancer therapeutics. These studies are still in their infancy and require further therapeutic validation, but the future appears bright for finally harnessing p53's tumour suppressing ability.

    AB - Since the discovery of p53, a vast wealth of knowledge on its function and regulation has been accumulated. It is known that it is a key tumour suppressor and that its function is lost in many types of cancers, either by mutation or by excessive negative regulation. Recently, several discoveries have re-energised p53 as a therapeutic target as it has been shown that reintroduction of functional p53 into tumours has a therapeutic benefit. These encouraging results clearly justify the search for small molecules that diminish negative regulation Of p53 in tumour cells, where p53 is not mutated as well as compounds that reactivate mutant p53. Important findings have been made to deal with both situations. Additionally, some of the small molecules identified may also help reduce the side effects of commonly used cancer therapeutics. These studies are still in their infancy and require further therapeutic validation, but the future appears bright for finally harnessing p53's tumour suppressing ability.

    KW - p53

    KW - Therapy

    KW - Tenovin

    KW - Prima

    KW - Nutlin

    KW - Tumor suppressor P53

    KW - Wild type P53

    KW - Nuclear export

    KW - SV40 transformed cells

    KW - Cancer therapy

    KW - Breast cancer

    KW - Mutant P53

    KW - MDM2

    KW - Activation

    KW - Pathway

    M3 - Review article

    VL - 6

    SP - 240

    EP - 243

    JO - Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

    JF - Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

    SN - 1479-666X

    IS - 4

    ER -